[go: up one dir, main page]

PE20131062A1 - Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias, metodo no invasivo para su deteccion en muestras fecales y kit para su realizacion - Google Patents

Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias, metodo no invasivo para su deteccion en muestras fecales y kit para su realizacion

Info

Publication number
PE20131062A1
PE20131062A1 PE2013000131A PE2013000131A PE20131062A1 PE 20131062 A1 PE20131062 A1 PE 20131062A1 PE 2013000131 A PE2013000131 A PE 2013000131A PE 2013000131 A PE2013000131 A PE 2013000131A PE 20131062 A1 PE20131062 A1 PE 20131062A1
Authority
PE
Peru
Prior art keywords
hmgb1
detection
kit
realization
fecal samples
Prior art date
Application number
PE2013000131A
Other languages
English (en)
Inventor
Salvatore Cucchiara
Laura Stronati
Roberta Vitali
Original Assignee
Dmg Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dmg Italia Srl filed Critical Dmg Italia Srl
Publication of PE20131062A1 publication Critical patent/PE20131062A1/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875Nucleoproteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

REFERIDA A UN METODO DE DETECCION DEL NIVEL DEL MARCO DE GRUPO DE ALTA MOVILIDAD 1 (HMGB1) EN MUESTRAS FECALES QUE COMPRENDE EL PESAJE DE LA MUESTRA FECAL Y SUSPENSION EN EL BUFFER DE EXTRACCION PBS, HOMOGENIZACION DE LA MUESTRA, CENTRIFUGACION Y EXTRACCION DEL SUPERNADANTE, EVALUACION DE LA CONCENTRACION DE PROTEINA Y ANALISIS DE LOS EXTRACTOS FECALES CON INMUNOTRANSFERENCIA. TAMBIEN ESTA REFERIDA A UN KIT COLORIMETRICO PARA LA DETECCION DE LA PROTEINA HMGB1
PE2013000131A 2010-08-05 2011-08-01 Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias, metodo no invasivo para su deteccion en muestras fecales y kit para su realizacion PE20131062A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM2010A000442A IT1406051B1 (it) 2010-08-05 2010-08-05 Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.

Publications (1)

Publication Number Publication Date
PE20131062A1 true PE20131062A1 (es) 2013-10-16

Family

ID=43739596

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000131A PE20131062A1 (es) 2010-08-05 2011-08-01 Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias, metodo no invasivo para su deteccion en muestras fecales y kit para su realizacion

Country Status (14)

Country Link
US (1) US20130137123A1 (es)
EP (1) EP2601525A1 (es)
JP (1) JP2013534313A (es)
CN (1) CN103069276A (es)
AU (1) AU2011287193B2 (es)
BR (1) BR112013002145A2 (es)
CA (1) CA2807107C (es)
CL (1) CL2013000223A1 (es)
EA (1) EA201390197A1 (es)
IL (1) IL223845A (es)
IT (1) IT1406051B1 (es)
MX (1) MX2013001327A (es)
PE (1) PE20131062A1 (es)
WO (1) WO2012017466A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105451755B (zh) 2013-03-15 2020-10-13 领导医疗有限公司 铁调素类似物和其用途
EP3094973B1 (en) 2013-11-07 2020-07-29 Diagnodus Limited Biomarkers
EP3960754A3 (en) 2014-05-16 2022-07-06 Protagonist Therapeutics, Inc. Alpha4beta7 integrin thioether peptide antagonists
EP4378536A3 (en) 2014-07-17 2024-10-09 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
US20200064357A1 (en) * 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
KR20200006108A (ko) 2017-05-12 2020-01-17 에보니크 오퍼레이션즈 게엠베하 동물에서 씨. 퍼프린젠스 유발된 질환을 검출하는 방법
IT201700083044A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della gelsolina come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
IT201700083055A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della proteina inibitore 2 della dissociazione di rho gdp come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3092519A1 (en) * 2018-03-02 2019-09-06 Evonik Operations Gmbh In vitro method for detecting intestinal barrier failure in animals by determining ovotransferrin
CN109030817A (zh) * 2018-07-04 2018-12-18 长沙都正医学检验有限责任公司 Hmgb1检测试剂盒及其制备方法
EP3894863B1 (en) 2018-12-14 2022-11-23 Evonik Operations GmbH In vitro method for detecting avian intestinal dysbiosis
US11684653B2 (en) * 2019-03-06 2023-06-27 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms
RS66991B1 (sr) 2020-01-15 2025-08-29 Janssen Biotech Inc Peptidni inhibitori interleukin-23 receptora i njihova primena u lečenju inflamatornih bolesti
US12018057B2 (en) 2020-01-15 2024-06-25 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
KR20230110570A (ko) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물
UY39857A (es) 2021-07-14 2023-02-28 Janssen Biotech Inc Inhibidores peptídicos lipidados del receptor de interleucina-23
CN116973572B (zh) * 2023-06-02 2025-03-07 东南大学附属中大医院 基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1577671A1 (en) * 1996-07-17 2005-09-21 Kaneka Corporation Diagnostic drugs for autoimmune diseases
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7700307B2 (en) * 2003-03-08 2010-04-20 Auvation Limited Mitochondrial stress-70 protein markers for colorectal cancer
KR20070090890A (ko) * 2004-10-22 2007-09-06 메디뮨 인코포레이티드 Hmgb1에 대한 고 친화성 항체 및 이의 사용 방법
US20090297546A1 (en) * 2006-12-20 2009-12-03 Shino-Test Corporation Avian-derived antibody capable of binding specifically to human hmgb1, immunological determination method for human hmgb1, and immunological determination reagent for human hmgb1
CA2695360A1 (en) * 2007-08-02 2009-02-05 Iss Immune System Stimulation Ab Diagnosis, staging and monitoring of inflammatory bowel disease
KR20100124326A (ko) * 2008-03-14 2010-11-26 엑사젠 다이어그노스틱스, 인코포레이티드 염증성 장 질병 및 과민성 장 증후군에 대한 생체마커

Also Published As

Publication number Publication date
IT1406051B1 (it) 2014-02-06
WO2012017466A1 (en) 2012-02-09
EP2601525A1 (en) 2013-06-12
EA201390197A1 (ru) 2013-06-28
IL223845A (en) 2016-06-30
AU2011287193B2 (en) 2015-08-13
BR112013002145A2 (pt) 2016-05-24
MX2013001327A (es) 2013-03-08
WO2012017466A8 (en) 2013-07-11
CA2807107A1 (en) 2012-02-09
JP2013534313A (ja) 2013-09-02
CN103069276A (zh) 2013-04-24
ITRM20100442A1 (it) 2012-02-06
CL2013000223A1 (es) 2014-03-28
CA2807107C (en) 2017-01-03
AU2011287193A1 (en) 2013-06-13
US20130137123A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
PE20131062A1 (es) Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias, metodo no invasivo para su deteccion en muestras fecales y kit para su realizacion
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
BRPI1007867B8 (pt) anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente
BR112015026248A2 (pt) dispositivo de coleta de fluido biológico e sistema de separação e teste de fluido biológico
MX2020009278A (es) Ensayos para detectar la neurodegeneración.
BR112015026242A2 (pt) dispositivo de coleta de fluido biológico e sistema de separação e testagem de fluido biológico
CO2019008675A2 (es) Anticuerpos anti-lag3 radiomarcados para la obtención de imágenes mediante inmuno-pet
PE20141450A1 (es) Ensayo de lisiloxidasa-homologo 2 y metodos de uso del mismo
BRPI0720707A2 (pt) Sistema de teste para uso com um tampão para testar a presença de moléculas alvo de um ou mais tipos de alvo em uma amostra de teste biológico; sistema de teste para testar a presença de moléculas alvo de um ou mais tipos de alvo em uma amostra de teste biológico; e método de focalização de moléculas para facilitar um teste da presença de moléculas alvo de um ou mais tipos de alvo de uma amostra de teste biológico.
EP4273551A3 (en) Multiplexed total antibody and antibody-conjugated drug quantification assay
BR112015026246A2 (pt) dispositivo de transferência de coleta de sangue e separação de sangue e sistema de teste
AR053948A1 (es) Deteccion de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapeutico correspondiente
AR083259A1 (es) Cuantificacion y caracterizacion de los alergenos
ES2684758T3 (es) Procedimiento para diagnosticar fibrosis hepática
BR112014031958A2 (pt) bag3 como marcador de tecido e soro bioquímico
AR071034A1 (es) Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor
CY1121482T1 (el) Ευαισθητη πολυπλεκτικη ανοσοδοκιμασια για τους διαλυτους υποδοχεις των αυξητικων παραγοντων των ινοβλαστων
EA201400356A1 (ru) Иммуноанализ для обнаружения антибиотиков
Fernández-Niño et al. Agreement of the Kato-Katz test established by the WHO with samples fixed with sodium acetate analyzed at 6 months to diagnose intestinal geohelminthes
Le Gall‐Lanotto et al. Road‐traffic‐related air pollution contributes to skin barrier alteration and growth defect of sensory neurons
PE20121648A1 (es) Procedimiento de identificacion de animales vacunados frente a brucella
BR112012027535A2 (pt) método para a detecção da susceptibilidade em desenvolver efeitos colaterais adversos relacionados com bioimplantes
BR112017020539B8 (pt) Reagente para imunoensaio compreendendo um polipeptídeo, métodos de detecção de anticorpos e/ou antígenos para o vírus da hepatite c em uma amostra biológica, de seleção de amostras biológicas de um suprimento de amostras biológicas humanas, bem como polipeptídeo isolado e kit para teste imunodiagnóstico
ZHOU et al. Effect of two different kits on blood concentration of tacrolimus in liver transplantation
WANG et al. Clinical value of urine heparin-binding protein in the diagnosis of urinary tract infection

Legal Events

Date Code Title Description
FA Abandonment or withdrawal